Northwest Biotherapeutics (NWBO) Accumulated Depreciation & Amortization (2016 - 2025)
Northwest Biotherapeutics (NWBO) has 16 years of Accumulated Depreciation & Amortization data on record, last reported at $1.3 million in Q3 2025.
- For Q3 2025, Accumulated Depreciation & Amortization changed 0.0% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, changed 0.0%, while the annual FY2024 figure was $1.8 million, 110.34% up from the prior year.
- Accumulated Depreciation & Amortization reached $1.3 million in Q3 2025 per NWBO's latest filing, up from $900000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $1.8 million in Q4 2024 and bottomed at -$17.2 million in Q4 2023.
- Average Accumulated Depreciation & Amortization over 5 years is -$3.1 million, with a median of $400000.0 recorded in 2024.
- Peak YoY movement for Accumulated Depreciation & Amortization: crashed 4840.23% in 2023, then surged 110.34% in 2024.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at -$1.1 million in 2021, then skyrocketed by 68.85% to -$348000.0 in 2022, then plummeted by 4840.23% to -$17.2 million in 2023, then soared by 110.34% to $1.8 million in 2024, then dropped by 26.84% to $1.3 million in 2025.
- Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $1.3 million in Q3 2025, $900000.0 in Q2 2025, and $400000.0 in Q1 2025.